AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The injectable antibiotic can also used for cIAI caused by all those organisms, plus seven Bacteroides strains, Citrobacter freundii, Fusobacterium nucleatum, Klebsiella oxytoca and ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

"Antibiotics reduce the diversity of the ... the greater the likelihood that some strains such as Klebsiella oxytoca will ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...

Blood cultures and cultures of the tip of a central venous catheter yielded Klebsiella oxytoca. Bullae formed ... infant was treated with broad-spectrum antibiotics, ventilation, diuretics ...

Overuse of antibiotics is the main cause of the so-called “silent pandemic” of AMR infections, with a type of infection called Klebsiella pneumoniae now becoming a major issue for hospitals ...